GlaxoSmithKline (GSK) has signed an agreement to help make up to 60 million doses of Novavax’s COVID-19 vaccine NVX-CoV2373 in the UK. The agreement between GSK, Novavax and the UK Vaccines Taskforce ...

Regulators in the United Kingdom have approved full marketing authorization for Gaithersburg-based Novavax’s updated, protein-based COVID-19 booster shot, but regulators in the European Union have ...

Novavax, Inc. recently announced at the Jefferies London Healthcare Conference 2025 that it is shifting its focus from direct COVID-19 commercial operations to an expanded research and development ...

Novavax will refund $123.8 million to the UK agency in quarterly payments of $10.3 million over three years. The two parties initially entered into a COVID-19 vaccine supply deal in 2020. Get access ...

Novavax, Inc. (NASDAQ:NVAX) ranks among the most oversold biotech stocks to invest in. Novavax, Inc. (NASDAQ:NVAX) announced ...

Gaithersburg, Maryland-based Novavax has filed for approval for use of its COVID-19 vaccine in teenagers in the U.K. The application, with the Medicines and Healthcare Products Regulatory Agency of ...

A new Covid-19 vaccine from Novavax was 89% effective and appeared to offer protection against some variants of the coronavirus in a clinical trial conducted in the UK, the American biotech firm has ...

(RTTNews) - Novavax, Inc. (NVAX), a vaccine maker focused on serious infectious diseases, said on Tuesday that an initial one million doses of Nuvaxovid or NVX-CoV2373 Covid-19 vaccine are now ready ...

Novavax says its COVID-19 vaccine appears 89% effective, based on early findings from a British study. According to USA Today, the two-dose vaccine was just 60% effective in the South African trial.

Novavax released its FY22 earnings last week. The news was not good. Although the company did make product sales of $1.6bn, it made a substantial loss of >$650, after a >$1.7bn loss in the prior year.

Novavax Inc. said Thursday that its COVID-19 vaccine appears 89% effective based on early findings from a British study and that it also seems to work — though not quite as well — against new mutated ...